Amgen Inc. has been gaining notable attention from investors and financial institutions alike. The US FDA has approved Amgen's colorectal cancer therapy, including the groundbreaking LUMAKRAS Combination Therapy. This has strengthened the company's potential long-term growth. Notable mentions include Boston Common Asset Management and Avanza Fonder making significant new investments in Amgen. The company continues to attract investor interest due to its strong dividend payments, with the upcoming dividend announced to be larger than the previous year's. Despite occasional dips correlating with market fluctuations, Amgen's stock validates its position as a top momentum stock for long term. The company is also making strides within the biotech sector, achieving robust weight loss results in Phase 2 study of Maritide for treating obesity. At the same time, Amgen's tarlatamab has been granted conditional marketing authorization for third-line treatment of small cell lung cancer in the UK. Amgen has also reported promising Q3 earnings and announced a 2025 first-quarter dividend. The company's innovation is evident in their recent research appointments and continuous data presentation in rare inflammatory disease treatments.
Amgen AMGN News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Sun, 19 Jan 2025 00:05:00 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -5
